肾炎康复片联合缬沙坦治疗糖尿病肾病的临床观察

Clinical study of Shenyan kangfu tablet combined with Valsartan in the treatment of diabetic enphropathy

目的:探讨肾炎康复片联合缬沙坦治疗中晚期糖尿病肾病的疗效及安全性。方法:将98例糖尿病肾病4期患者随机分为肾炎康复片联合缬沙坦组(联合组)50例、缬沙坦组48例,评估两组治疗3个月后疗效差异,并检测治疗前后血糖、血压、血脂、24 h尿蛋白定量、血肌酐及ALT水平。结果:治疗3个月后联合组临床疗效总有效率84%,显著高于缬沙坦组(71%);联合组24 h尿蛋白定量水平[(0.59±0.39)g]亦明显低于缬沙坦组[(0.98±0.57)g]。两组均未见明显不良反应。结论:肾炎康复片联合缬沙坦比单用缬沙坦更能有效降低中晚期糖尿病肾病患者的蛋白尿,短期使用未见明显不良反应。

Objective： To observe the therapeutic efficacy of Shenyan kangfu tablet combined with Valsartan in the treatment of diabetic nephropathy. Methods： Ninety-eight cases of stage 4 diabetic nephropathy were randomly divided into two groups ： Shenyan Kangfu Tablet combined with Valsartan group （ combination group, n = 50） and Valsartan group （ARB group, n = 48）. The blood pressure, plasma glucose and lipids, 24 hour urinary protein, plasma creatinine and alanine transarninase were assessed after 3-month treatment. Results： The total therapeutic efficacy in combination group （84%） was significant higher than that in ARB group （70%）, with significantly lower 24 hour urinary protein [ （0. 59 ~ 0. 39） g vs （0. 98 ~ 0. 57） g ]. No adverse event was reported. Conclusion ： Shenyan kangfu tablet combined with Valsartan is effective for treatment of late stage of diabetic nephropathy.